Plain-English translation of NCT06702566 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
Researchers want to understand whether a protein called ferritin in your blood can help doctors predict and diagnose serious side effects that sometimes happen when people receive immunotherapy for cancer. This trial will compare ferritin levels in 1,500 patients receiving different types of cancer treatment—including immunotherapy, targeted therapy, and chemotherapy—to see if ferritin measurements can serve as an early warning sign of these complications.
Immunotherapy is an effective cancer treatment, but it can trigger serious immune-related side effects in some patients. Doctors currently diagnose these side effects after symptoms appear, which can delay treatment. This study aims to find a simple, fast blood test that could alert doctors to these problems earlier, before they become severe.
You likely qualify if…
You likely don't qualify if…
You will receive your scheduled cancer treatment as planned by your doctor. At the beginning of the study, you'll have blood tests and imaging scans. If you develop any side effects during treatment, a specialized team of doctors will evaluate you, and you'll have blood drawn every 3 days (at least 3 times) to measure ferritin and other markers until you recover. If you don't experience side effects, you'll have repeat blood tests every 4 treatment cycles. The study tracks whether ferritin levels can reliably predict which patients will develop serious immunotherapy side effects.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Enrollment target
~1,500 participants
Started
July 2024
Primary completion
July 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in November 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Liang Liu, M.D
ianjin Medical University Cancer Institute and Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.